NLRP3 and diabetic kidney disease: By blocking the NLRP3/caspase-1/IL-1 pathway and lowering urinary NGAL levels in mice with a model of diabetic nephropathy, researchers demonstrated that MCC950 might significantly alleviate diabetic chronic kidney injury [25].